FLT3 and acute myeloid leukemia: Incidence of infection appeared to be similar in a pivotal trial of midostaurin versus placebo in combination with standard chemotherapy for treatment of FLT-3 mutated AML, though in another similar study of gilterinib there were more fatal infectious events in the gilterinib group (28 vs. 7) [138,139].